Cancer Stem Cell NewsAll Articles by Author:
Emily Salmini
Hematopoiesis News
NYNRIN Safeguards Leukemia Stem Cells by Sustaining Thioredoxin Activity to Maintain Redox Homeostasis
[Nature Communications] Genetic targeting of NYN domain and retroviral integrase containing (NYNRIN) impairs leukemia stem cell (LSC)-like cell maintenance and in vivo leukemogenic capacity in MLL-AF9- and HOXA9/MEIS1-driven AML models, and compromises the in vivo pathogenicity of patient-derived LSC-like cells.
Hematopoiesis News
The Maternal-Fetal Interface Is an Early Hematopoietic Niche Enriched in Distinct Erythro-Myeloid Progenitors
[Nature Immunology] Researchers identified a previously unrecognized hematopoietic site at the maternal–fetal interface in mice, termed MIXER (Maternally Interfaced eXtraEmbRyonic) tissue, which develops contemporaneously with the yolk sac and exhibits robust hematopoietic activity.
Hematopoiesis News
Developmental Cues and Stage‑Matched Niches for Engineering Engraftable Human HSCs
[Experimental Hematology] Scientists integrated insights from both developmental and engineered systems to outline shared principles of human HSC formation and highlight opportunities to refine in vitro strategies for producing fully functional HSCs.
Hematopoiesis News
Transient ATM Inhibition Enhances Knock-in Efficiency in Hematopoietic Stem Cells by Attenuating the DNA Damage Response
[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated that transient inhibition of Ataxia-Telangiectasia Mutated (ATM) kinase markedly enhanced KI efficiency in mouse HSCs genome-edited with Cas9/ribonucleoprotein and AAV donor DNA.
Hematopoiesis News
Serine Auxotrophy Is a Targetable Vulnerability Driven by PSAT1 Suppression in AML
[Leukemia] The authors reported that a subset of human AML cell lines and primary samples are completely dependent on external serine, known as serine auxotrophy.
Hematopoiesis News
A Scalable, Antibody-Free Lipid Nanoparticle Achieves Preferential mRNA Delivery to Human HSPCs In Vivo Without Conditioning
[Molecular Therapy] Scientists reported a scalable, ligand-free hematopoietic stem and progenitor cells (HSPCs)-tropic lipid nanoparticle enabling efficient mRNA delivery to human HSPCs in vivo without conditioning.
Popular
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
[VivoSim Labs, Inc. ] VivoSim Labs, Inc., a provider of next-generation New Approach Methodologies (NAM) 3D human cellular models for preclinical safety and efficacy, announced that it is extending its human tissue platform beyond toxicology with efficacy testing services built on NAMkind™ disease models of the liver and intestine.
Acta Pharmaceuticals Closes $24 Million in Seed Financing for Alzheimer’s Disease Pipeline Targeting Early Intervention and Prevention
[ Acta Pharmaceuticals, Inc.] Acta Pharmaceuticals, Inc. announced $24 million in total seed financing to advance a pipeline of therapies designed for early intervention in Alzheimer’s disease. Acta’s Combination Therapies program builds on decades of research using Alzheimer’s-in-a-Dish™, laboratory models of human brain cells in mini-organoids and “assembloids”.
Upstate Receives $1.5 Million to Advance Brain Disease Research
[Upstate Medical University] Upstate Medical University has been awarded $1.5 million by New York state to create an advanced research center for brain diseases. Upstate will establish the Biospecimen-iPSC-Organoid Node, which will integrate biospecimens, induced pluripotent stem cells and organoid models to support human-centered neuroscience research.
